Sangamo Therapeutics (OTC: SGMO) reported Q1 EPS of ($0.08), $0.02 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $1.4 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.